Relay Therapeutics recently reported interim subset data from its ReDiscover first-in-human trial, showing zovegalisib plus fulvestrant delivered meaningful progression-free survival and response ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback